nodes	percent_of_prediction	percent_of_DWPC	metapath
Mesalazine—PTGS2—head and neck cancer	0.579	1	CbGaD
Mesalazine—MPO—saliva—head and neck cancer	0.00522	0.114	CbGeAlD
Mesalazine—CHUK—connective tissue—head and neck cancer	0.00254	0.0555	CbGeAlD
Mesalazine—CHUK—epithelium—head and neck cancer	0.00241	0.0527	CbGeAlD
Mesalazine—PTGS2—cartilage tissue—head and neck cancer	0.00221	0.0482	CbGeAlD
Mesalazine—CHUK—lymphoid tissue—head and neck cancer	0.00186	0.0406	CbGeAlD
Mesalazine—IKBKB—connective tissue—head and neck cancer	0.00173	0.0377	CbGeAlD
Mesalazine—CHUK—thyroid gland—head and neck cancer	0.00169	0.0369	CbGeAlD
Mesalazine—PPARG—neck—head and neck cancer	0.0015	0.0328	CbGeAlD
Mesalazine—CHUK—head—head and neck cancer	0.0015	0.0327	CbGeAlD
Mesalazine—ALOX5—connective tissue—head and neck cancer	0.00143	0.0313	CbGeAlD
Mesalazine—Salicylate-sodium—PTGS2—head and neck cancer	0.00138	0.3	CrCbGaD
Mesalazine—IKBKB—lymphoid tissue—head and neck cancer	0.00126	0.0276	CbGeAlD
Mesalazine—MPO—connective tissue—head and neck cancer	0.00121	0.0265	CbGeAlD
Mesalazine—MPO—epithelium—head and neck cancer	0.00115	0.0251	CbGeAlD
Mesalazine—IKBKB—thyroid gland—head and neck cancer	0.00115	0.0251	CbGeAlD
Mesalazine—PPARG—connective tissue—head and neck cancer	0.00107	0.0235	CbGeAlD
Mesalazine—CHUK—lymph node—head and neck cancer	0.00105	0.0229	CbGeAlD
Mesalazine—ALOX5—lymphoid tissue—head and neck cancer	0.00105	0.0229	CbGeAlD
Mesalazine—PPARG—epithelium—head and neck cancer	0.00102	0.0223	CbGeAlD
Mesalazine—IKBKB—head—head and neck cancer	0.00102	0.0222	CbGeAlD
Mesalazine—ALOX5—thyroid gland—head and neck cancer	0.00095	0.0208	CbGeAlD
Mesalazine—Olsalazine—PTGS2—head and neck cancer	0.000944	0.206	CrCbGaD
Mesalazine—PTGS2—mouth—head and neck cancer	0.000896	0.0196	CbGeAlD
Mesalazine—Diflunisal—PTGS2—head and neck cancer	0.000888	0.193	CrCbGaD
Mesalazine—Aminosalicylic Acid—PTGS2—head and neck cancer	0.000888	0.193	CrCbGaD
Mesalazine—MPO—lymphoid tissue—head and neck cancer	0.000885	0.0193	CbGeAlD
Mesalazine—ALOX5—head—head and neck cancer	0.000843	0.0184	CbGeAlD
Mesalazine—PPARG—lymphoid tissue—head and neck cancer	0.000786	0.0172	CbGeAlD
Mesalazine—PPARG—thyroid gland—head and neck cancer	0.000714	0.0156	CbGeAlD
Mesalazine—MPO—head—head and neck cancer	0.000713	0.0156	CbGeAlD
Mesalazine—IKBKB—lymph node—head and neck cancer	0.000712	0.0156	CbGeAlD
Mesalazine—PPARG—head—head and neck cancer	0.000633	0.0138	CbGeAlD
Mesalazine—Oropharyngeal pain—Docetaxel—head and neck cancer	0.000618	0.0035	CcSEcCtD
Mesalazine—Weight increased—Hydroxyurea—head and neck cancer	0.000618	0.00349	CcSEcCtD
Mesalazine—Infestation—Hydroxyurea—head and neck cancer	0.000605	0.00342	CcSEcCtD
Mesalazine—Infestation NOS—Hydroxyurea—head and neck cancer	0.000605	0.00342	CcSEcCtD
Mesalazine—Haemoglobin—Vinblastine—head and neck cancer	0.000599	0.00339	CcSEcCtD
Mesalazine—Haemorrhage—Vinblastine—head and neck cancer	0.000596	0.00337	CcSEcCtD
Mesalazine—Blood bilirubin increased—Docetaxel—head and neck cancer	0.000594	0.00336	CcSEcCtD
Mesalazine—Neuropathy peripheral—Hydroxyurea—head and neck cancer	0.000593	0.00336	CcSEcCtD
Mesalazine—Dermatitis bullous—Fluorouracil—head and neck cancer	0.000592	0.00335	CcSEcCtD
Mesalazine—Pharyngitis—Vinblastine—head and neck cancer	0.000591	0.00334	CcSEcCtD
Mesalazine—ALOX5—lymph node—head and neck cancer	0.00059	0.0129	CbGeAlD
Mesalazine—Stomatitis—Hydroxyurea—head and neck cancer	0.00059	0.00334	CcSEcCtD
Mesalazine—Lethargy—Fluorouracil—head and neck cancer	0.000577	0.00326	CcSEcCtD
Mesalazine—PTGS1—connective tissue—head and neck cancer	0.000574	0.0126	CbGeAlD
Mesalazine—Hepatobiliary disease—Hydroxyurea—head and neck cancer	0.000573	0.00324	CcSEcCtD
Mesalazine—Gastrointestinal haemorrhage—Fluorouracil—head and neck cancer	0.000566	0.0032	CcSEcCtD
Mesalazine—Osteoarthritis—Fluorouracil—head and neck cancer	0.000566	0.0032	CcSEcCtD
Mesalazine—Hepatocellular injury—Docetaxel—head and neck cancer	0.000562	0.00318	CcSEcCtD
Mesalazine—Phosphatase alkaline increased—Docetaxel—head and neck cancer	0.000562	0.00318	CcSEcCtD
Mesalazine—PTGS2—connective tissue—head and neck cancer	0.000549	0.012	CbGeAlD
Mesalazine—Haemoglobin—Hydroxyurea—head and neck cancer	0.000546	0.00309	CcSEcCtD
Mesalazine—Influenza like illness—Docetaxel—head and neck cancer	0.000546	0.00309	CcSEcCtD
Mesalazine—PTGS1—epithelium—head and neck cancer	0.000545	0.0119	CbGeAlD
Mesalazine—Haemorrhage—Hydroxyurea—head and neck cancer	0.000544	0.00307	CcSEcCtD
Mesalazine—Colitis—Docetaxel—head and neck cancer	0.00054	0.00305	CcSEcCtD
Mesalazine—Candida infection—Docetaxel—head and neck cancer	0.000537	0.00304	CcSEcCtD
Mesalazine—Skin exfoliation—Docetaxel—head and neck cancer	0.000537	0.00304	CcSEcCtD
Mesalazine—Neuropathy—Docetaxel—head and neck cancer	0.000528	0.00299	CcSEcCtD
Mesalazine—Alopecia—Vinblastine—head and neck cancer	0.000527	0.00298	CcSEcCtD
Mesalazine—PTGS2—epithelium—head and neck cancer	0.000521	0.0114	CbGeAlD
Mesalazine—Dry skin—Fluorouracil—head and neck cancer	0.000518	0.00293	CcSEcCtD
Mesalazine—Nasopharyngitis—Fluorouracil—head and neck cancer	0.000506	0.00286	CcSEcCtD
Mesalazine—MPO—lymph node—head and neck cancer	0.0005	0.0109	CbGeAlD
Mesalazine—Salicylic acid—PTGS2—head and neck cancer	0.000494	0.108	CrCbGaD
Mesalazine—Angiopathy—Hydroxyurea—head and neck cancer	0.000493	0.00279	CcSEcCtD
Mesalazine—Dysphagia—Fluorouracil—head and neck cancer	0.000489	0.00276	CcSEcCtD
Mesalazine—Chills—Hydroxyurea—head and neck cancer	0.000488	0.00276	CcSEcCtD
Mesalazine—Eosinophilia—Fluorouracil—head and neck cancer	0.000484	0.00274	CcSEcCtD
Mesalazine—PTGS1—trachea—head and neck cancer	0.000482	0.0105	CbGeAlD
Mesalazine—Ill-defined disorder—Vinblastine—head and neck cancer	0.000481	0.00272	CcSEcCtD
Mesalazine—Alopecia—Hydroxyurea—head and neck cancer	0.00048	0.00272	CcSEcCtD
Mesalazine—Anaemia—Vinblastine—head and neck cancer	0.00048	0.00271	CcSEcCtD
Mesalazine—Angina pectoris—Fluorouracil—head and neck cancer	0.000476	0.00269	CcSEcCtD
Mesalazine—Erythema—Hydroxyurea—head and neck cancer	0.000473	0.00268	CcSEcCtD
Mesalazine—Blood alkaline phosphatase increased—Docetaxel—head and neck cancer	0.000469	0.00265	CcSEcCtD
Mesalazine—Malaise—Vinblastine—head and neck cancer	0.000468	0.00265	CcSEcCtD
Mesalazine—Vertigo—Vinblastine—head and neck cancer	0.000466	0.00264	CcSEcCtD
Mesalazine—Leukopenia—Vinblastine—head and neck cancer	0.000464	0.00263	CcSEcCtD
Mesalazine—Pancytopenia—Fluorouracil—head and neck cancer	0.000464	0.00262	CcSEcCtD
Mesalazine—PTGS2—trachea—head and neck cancer	0.000461	0.0101	CbGeAlD
Mesalazine—Deafness—Docetaxel—head and neck cancer	0.000456	0.00258	CcSEcCtD
Mesalazine—Upper respiratory tract infection—Fluorouracil—head and neck cancer	0.000454	0.00257	CcSEcCtD
Mesalazine—Hepatic failure—Docetaxel—head and neck cancer	0.000454	0.00257	CcSEcCtD
Mesalazine—Hypertension—Vinblastine—head and neck cancer	0.000448	0.00253	CcSEcCtD
Mesalazine—Photosensitivity reaction—Fluorouracil—head and neck cancer	0.000446	0.00252	CcSEcCtD
Mesalazine—PPARG—lymph node—head and neck cancer	0.000443	0.00969	CbGeAlD
Mesalazine—Ill-defined disorder—Hydroxyurea—head and neck cancer	0.000439	0.00248	CcSEcCtD
Mesalazine—Pneumonia—Fluorouracil—head and neck cancer	0.000438	0.00248	CcSEcCtD
Mesalazine—Anaemia—Hydroxyurea—head and neck cancer	0.000437	0.00247	CcSEcCtD
Mesalazine—Discomfort—Vinblastine—head and neck cancer	0.000436	0.00247	CcSEcCtD
Mesalazine—Infestation—Fluorouracil—head and neck cancer	0.000436	0.00246	CcSEcCtD
Mesalazine—Infestation NOS—Fluorouracil—head and neck cancer	0.000436	0.00246	CcSEcCtD
Mesalazine—Atrial fibrillation—Docetaxel—head and neck cancer	0.000431	0.00244	CcSEcCtD
Mesalazine—Renal impairment—Docetaxel—head and neck cancer	0.000429	0.00243	CcSEcCtD
Mesalazine—Neuropathy peripheral—Fluorouracil—head and neck cancer	0.000427	0.00242	CcSEcCtD
Mesalazine—Dermatitis bullous—Docetaxel—head and neck cancer	0.000427	0.00241	CcSEcCtD
Mesalazine—Malaise—Hydroxyurea—head and neck cancer	0.000427	0.00241	CcSEcCtD
Mesalazine—Stomatitis—Fluorouracil—head and neck cancer	0.000425	0.0024	CcSEcCtD
Mesalazine—Urinary tract infection—Fluorouracil—head and neck cancer	0.000424	0.0024	CcSEcCtD
Mesalazine—Conjunctivitis—Fluorouracil—head and neck cancer	0.000424	0.0024	CcSEcCtD
Mesalazine—Leukopenia—Hydroxyurea—head and neck cancer	0.000424	0.00239	CcSEcCtD
Mesalazine—Lethargy—Docetaxel—head and neck cancer	0.000417	0.00236	CcSEcCtD
Mesalazine—Thrombocytopenia—Vinblastine—head and neck cancer	0.000415	0.00234	CcSEcCtD
Mesalazine—Epistaxis—Fluorouracil—head and neck cancer	0.000411	0.00232	CcSEcCtD
Mesalazine—Sinusitis—Fluorouracil—head and neck cancer	0.000409	0.00231	CcSEcCtD
Mesalazine—Gastrointestinal haemorrhage—Docetaxel—head and neck cancer	0.000408	0.00231	CcSEcCtD
Mesalazine—Agranulocytosis—Fluorouracil—head and neck cancer	0.000407	0.0023	CcSEcCtD
Mesalazine—Anorexia—Vinblastine—head and neck cancer	0.000404	0.00228	CcSEcCtD
Mesalazine—Migraine—Docetaxel—head and neck cancer	0.000402	0.00227	CcSEcCtD
Mesalazine—PTGS2—lymphoid tissue—head and neck cancer	0.000401	0.00877	CbGeAlD
Mesalazine—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—head and neck cancer	0.0004	0.00226	CcSEcCtD
Mesalazine—Discomfort—Hydroxyurea—head and neck cancer	0.000398	0.00225	CcSEcCtD
Mesalazine—Haemoglobin—Fluorouracil—head and neck cancer	0.000393	0.00222	CcSEcCtD
Mesalazine—Rhinitis—Fluorouracil—head and neck cancer	0.000392	0.00222	CcSEcCtD
Mesalazine—Haemorrhage—Fluorouracil—head and neck cancer	0.000391	0.00221	CcSEcCtD
Mesalazine—Pharyngitis—Fluorouracil—head and neck cancer	0.000388	0.0022	CcSEcCtD
Mesalazine—Oedema—Hydroxyurea—head and neck cancer	0.000386	0.00218	CcSEcCtD
Mesalazine—Infection—Hydroxyurea—head and neck cancer	0.000384	0.00217	CcSEcCtD
Mesalazine—PTGS1—thyroid gland—head and neck cancer	0.000381	0.00834	CbGeAlD
Mesalazine—Paraesthesia—Vinblastine—head and neck cancer	0.00038	0.00215	CcSEcCtD
Mesalazine—Nervous system disorder—Hydroxyurea—head and neck cancer	0.000379	0.00214	CcSEcCtD
Mesalazine—Thrombocytopenia—Hydroxyurea—head and neck cancer	0.000378	0.00214	CcSEcCtD
Mesalazine—Liver function test abnormal—Docetaxel—head and neck cancer	0.000377	0.00213	CcSEcCtD
Mesalazine—Skin disorder—Hydroxyurea—head and neck cancer	0.000375	0.00212	CcSEcCtD
Mesalazine—Dry skin—Docetaxel—head and neck cancer	0.000374	0.00212	CcSEcCtD
Mesalazine—Abdominal pain upper—Docetaxel—head and neck cancer	0.000373	0.00211	CcSEcCtD
Mesalazine—Orthostatic hypotension—Docetaxel—head and neck cancer	0.000373	0.00211	CcSEcCtD
Mesalazine—Breast disorder—Docetaxel—head and neck cancer	0.000369	0.00209	CcSEcCtD
Mesalazine—Anorexia—Hydroxyurea—head and neck cancer	0.000368	0.00208	CcSEcCtD
Mesalazine—Decreased appetite—Vinblastine—head and neck cancer	0.000368	0.00208	CcSEcCtD
Mesalazine—Cramp muscle—Docetaxel—head and neck cancer	0.000368	0.00208	CcSEcCtD
Mesalazine—Aspartate aminotransferase increased—Docetaxel—head and neck cancer	0.000368	0.00208	CcSEcCtD
Mesalazine—Nasopharyngitis—Docetaxel—head and neck cancer	0.000365	0.00206	CcSEcCtD
Mesalazine—Constipation—Vinblastine—head and neck cancer	0.000362	0.00205	CcSEcCtD
Mesalazine—Pain—Vinblastine—head and neck cancer	0.000362	0.00205	CcSEcCtD
Mesalazine—Alanine aminotransferase increased—Docetaxel—head and neck cancer	0.00036	0.00204	CcSEcCtD
Mesalazine—Dysphagia—Docetaxel—head and neck cancer	0.000353	0.00199	CcSEcCtD
Mesalazine—Feeling abnormal—Vinblastine—head and neck cancer	0.000349	0.00197	CcSEcCtD
Mesalazine—Bronchospasm—Docetaxel—head and neck cancer	0.000347	0.00196	CcSEcCtD
Mesalazine—Gastrointestinal pain—Vinblastine—head and neck cancer	0.000346	0.00196	CcSEcCtD
Mesalazine—Alopecia—Fluorouracil—head and neck cancer	0.000346	0.00195	CcSEcCtD
Mesalazine—Dyspnoea—Hydroxyurea—head and neck cancer	0.000344	0.00195	CcSEcCtD
Mesalazine—Angina pectoris—Docetaxel—head and neck cancer	0.000344	0.00194	CcSEcCtD
Mesalazine—Somnolence—Hydroxyurea—head and neck cancer	0.000343	0.00194	CcSEcCtD
Mesalazine—Erythema—Fluorouracil—head and neck cancer	0.000341	0.00193	CcSEcCtD
Mesalazine—Dyspepsia—Hydroxyurea—head and neck cancer	0.00034	0.00192	CcSEcCtD
Mesalazine—PTGS1—head—head and neck cancer	0.000338	0.0074	CbGeAlD
Mesalazine—Decreased appetite—Hydroxyurea—head and neck cancer	0.000336	0.0019	CcSEcCtD
Mesalazine—Pancytopenia—Docetaxel—head and neck cancer	0.000335	0.00189	CcSEcCtD
Mesalazine—Abdominal pain—Vinblastine—head and neck cancer	0.000335	0.00189	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	0.000333	0.00189	CcSEcCtD
Mesalazine—Fatigue—Hydroxyurea—head and neck cancer	0.000333	0.00188	CcSEcCtD
Mesalazine—Pain—Hydroxyurea—head and neck cancer	0.00033	0.00187	CcSEcCtD
Mesalazine—Constipation—Hydroxyurea—head and neck cancer	0.00033	0.00187	CcSEcCtD
Mesalazine—Neutropenia—Docetaxel—head and neck cancer	0.00033	0.00187	CcSEcCtD
Mesalazine—PTGS2—head—head and neck cancer	0.000323	0.00707	CbGeAlD
Mesalazine—Weight increased—Docetaxel—head and neck cancer	0.000321	0.00182	CcSEcCtD
Mesalazine—Vision blurred—Fluorouracil—head and neck cancer	0.000321	0.00181	CcSEcCtD
Mesalazine—Weight decreased—Docetaxel—head and neck cancer	0.000319	0.0018	CcSEcCtD
Mesalazine—Feeling abnormal—Hydroxyurea—head and neck cancer	0.000318	0.0018	CcSEcCtD
Mesalazine—Pneumonia—Docetaxel—head and neck cancer	0.000316	0.00179	CcSEcCtD
Mesalazine—Anaemia—Fluorouracil—head and neck cancer	0.000315	0.00178	CcSEcCtD
Mesalazine—Infestation—Docetaxel—head and neck cancer	0.000315	0.00178	CcSEcCtD
Mesalazine—Infestation NOS—Docetaxel—head and neck cancer	0.000315	0.00178	CcSEcCtD
Mesalazine—Hypersensitivity—Vinblastine—head and neck cancer	0.000312	0.00176	CcSEcCtD
Mesalazine—Stevens-Johnson syndrome—Docetaxel—head and neck cancer	0.000312	0.00176	CcSEcCtD
Mesalazine—Renal failure—Docetaxel—head and neck cancer	0.000309	0.00175	CcSEcCtD
Mesalazine—Neuropathy peripheral—Docetaxel—head and neck cancer	0.000308	0.00174	CcSEcCtD
Mesalazine—Jaundice—Docetaxel—head and neck cancer	0.000307	0.00173	CcSEcCtD
Mesalazine—Stomatitis—Docetaxel—head and neck cancer	0.000307	0.00173	CcSEcCtD
Mesalazine—Conjunctivitis—Docetaxel—head and neck cancer	0.000306	0.00173	CcSEcCtD
Mesalazine—Body temperature increased—Hydroxyurea—head and neck cancer	0.000305	0.00173	CcSEcCtD
Mesalazine—Leukopenia—Fluorouracil—head and neck cancer	0.000305	0.00172	CcSEcCtD
Mesalazine—Asthenia—Vinblastine—head and neck cancer	0.000304	0.00172	CcSEcCtD
Mesalazine—Hepatobiliary disease—Docetaxel—head and neck cancer	0.000297	0.00168	CcSEcCtD
Mesalazine—Epistaxis—Docetaxel—head and neck cancer	0.000297	0.00168	CcSEcCtD
Mesalazine—Agranulocytosis—Docetaxel—head and neck cancer	0.000294	0.00166	CcSEcCtD
Mesalazine—Chest pain—Fluorouracil—head and neck cancer	0.00029	0.00164	CcSEcCtD
Mesalazine—Myalgia—Fluorouracil—head and neck cancer	0.00029	0.00164	CcSEcCtD
Mesalazine—Diarrhoea—Vinblastine—head and neck cancer	0.00029	0.00164	CcSEcCtD
Mesalazine—Discomfort—Fluorouracil—head and neck cancer	0.000286	0.00162	CcSEcCtD
Mesalazine—Hypersensitivity—Hydroxyurea—head and neck cancer	0.000284	0.00161	CcSEcCtD
Mesalazine—Haemoglobin—Docetaxel—head and neck cancer	0.000284	0.0016	CcSEcCtD
Mesalazine—Rhinitis—Docetaxel—head and neck cancer	0.000283	0.0016	CcSEcCtD
Mesalazine—Haemorrhage—Docetaxel—head and neck cancer	0.000282	0.0016	CcSEcCtD
Mesalazine—Hepatitis—Docetaxel—head and neck cancer	0.000282	0.0016	CcSEcCtD
Mesalazine—Confusional state—Fluorouracil—head and neck cancer	0.00028	0.00158	CcSEcCtD
Mesalazine—Pharyngitis—Docetaxel—head and neck cancer	0.00028	0.00158	CcSEcCtD
Mesalazine—Dizziness—Vinblastine—head and neck cancer	0.00028	0.00158	CcSEcCtD
Mesalazine—Urinary tract disorder—Docetaxel—head and neck cancer	0.000279	0.00158	CcSEcCtD
Mesalazine—Oedema peripheral—Docetaxel—head and neck cancer	0.000278	0.00157	CcSEcCtD
Mesalazine—Oedema—Fluorouracil—head and neck cancer	0.000278	0.00157	CcSEcCtD
Mesalazine—Anaphylactic shock—Fluorouracil—head and neck cancer	0.000278	0.00157	CcSEcCtD
Mesalazine—Connective tissue disorder—Docetaxel—head and neck cancer	0.000277	0.00157	CcSEcCtD
Mesalazine—Asthenia—Hydroxyurea—head and neck cancer	0.000277	0.00157	CcSEcCtD
Mesalazine—Urethral disorder—Docetaxel—head and neck cancer	0.000277	0.00157	CcSEcCtD
Mesalazine—Infection—Fluorouracil—head and neck cancer	0.000276	0.00156	CcSEcCtD
Mesalazine—Nervous system disorder—Fluorouracil—head and neck cancer	0.000273	0.00154	CcSEcCtD
Mesalazine—Thrombocytopenia—Fluorouracil—head and neck cancer	0.000272	0.00154	CcSEcCtD
Mesalazine—Tachycardia—Fluorouracil—head and neck cancer	0.000271	0.00153	CcSEcCtD
Mesalazine—Vomiting—Vinblastine—head and neck cancer	0.000269	0.00152	CcSEcCtD
Mesalazine—Erythema multiforme—Docetaxel—head and neck cancer	0.000267	0.00151	CcSEcCtD
Mesalazine—Headache—Vinblastine—head and neck cancer	0.000265	0.0015	CcSEcCtD
Mesalazine—Anorexia—Fluorouracil—head and neck cancer	0.000265	0.0015	CcSEcCtD
Mesalazine—Diarrhoea—Hydroxyurea—head and neck cancer	0.000264	0.00149	CcSEcCtD
Mesalazine—Eye disorder—Docetaxel—head and neck cancer	0.000264	0.00149	CcSEcCtD
Mesalazine—Cardiac disorder—Docetaxel—head and neck cancer	0.000262	0.00148	CcSEcCtD
Mesalazine—Hypotension—Fluorouracil—head and neck cancer	0.00026	0.00147	CcSEcCtD
Mesalazine—Angiopathy—Docetaxel—head and neck cancer	0.000256	0.00145	CcSEcCtD
Mesalazine—Dizziness—Hydroxyurea—head and neck cancer	0.000255	0.00144	CcSEcCtD
Mesalazine—Immune system disorder—Docetaxel—head and neck cancer	0.000255	0.00144	CcSEcCtD
Mesalazine—Mediastinal disorder—Docetaxel—head and neck cancer	0.000254	0.00144	CcSEcCtD
Mesalazine—Chills—Docetaxel—head and neck cancer	0.000253	0.00143	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Fluorouracil—head and neck cancer	0.000253	0.00143	CcSEcCtD
Mesalazine—Nausea—Vinblastine—head and neck cancer	0.000252	0.00142	CcSEcCtD
Mesalazine—Insomnia—Fluorouracil—head and neck cancer	0.000251	0.00142	CcSEcCtD
Mesalazine—Paraesthesia—Fluorouracil—head and neck cancer	0.00025	0.00141	CcSEcCtD
Mesalazine—Alopecia—Docetaxel—head and neck cancer	0.00025	0.00141	CcSEcCtD
Mesalazine—Dyspnoea—Fluorouracil—head and neck cancer	0.000248	0.0014	CcSEcCtD
Mesalazine—Mental disorder—Docetaxel—head and neck cancer	0.000247	0.0014	CcSEcCtD
Mesalazine—Somnolence—Fluorouracil—head and neck cancer	0.000247	0.0014	CcSEcCtD
Mesalazine—Erythema—Docetaxel—head and neck cancer	0.000246	0.00139	CcSEcCtD
Mesalazine—Vomiting—Hydroxyurea—head and neck cancer	0.000246	0.00139	CcSEcCtD
Mesalazine—Dyspepsia—Fluorouracil—head and neck cancer	0.000245	0.00138	CcSEcCtD
Mesalazine—Rash—Hydroxyurea—head and neck cancer	0.000243	0.00138	CcSEcCtD
Mesalazine—Dermatitis—Hydroxyurea—head and neck cancer	0.000243	0.00138	CcSEcCtD
Mesalazine—Headache—Hydroxyurea—head and neck cancer	0.000242	0.00137	CcSEcCtD
Mesalazine—Decreased appetite—Fluorouracil—head and neck cancer	0.000242	0.00137	CcSEcCtD
Mesalazine—Dysgeusia—Docetaxel—head and neck cancer	0.000241	0.00136	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Fluorouracil—head and neck cancer	0.00024	0.00136	CcSEcCtD
Mesalazine—Back pain—Docetaxel—head and neck cancer	0.000238	0.00134	CcSEcCtD
Mesalazine—Pain—Fluorouracil—head and neck cancer	0.000238	0.00134	CcSEcCtD
Mesalazine—PTGS1—lymph node—head and neck cancer	0.000237	0.00518	CbGeAlD
Mesalazine—Muscle spasms—Docetaxel—head and neck cancer	0.000236	0.00134	CcSEcCtD
Mesalazine—Nausea—Hydroxyurea—head and neck cancer	0.000229	0.0013	CcSEcCtD
Mesalazine—Feeling abnormal—Fluorouracil—head and neck cancer	0.000229	0.0013	CcSEcCtD
Mesalazine—Anaemia—Docetaxel—head and neck cancer	0.000227	0.00128	CcSEcCtD
Mesalazine—PTGS2—lymph node—head and neck cancer	0.000227	0.00495	CbGeAlD
Mesalazine—Urticaria—Fluorouracil—head and neck cancer	0.000221	0.00125	CcSEcCtD
Mesalazine—Syncope—Docetaxel—head and neck cancer	0.00022	0.00125	CcSEcCtD
Mesalazine—Leukopenia—Docetaxel—head and neck cancer	0.00022	0.00124	CcSEcCtD
Mesalazine—Body temperature increased—Fluorouracil—head and neck cancer	0.00022	0.00124	CcSEcCtD
Mesalazine—Palpitations—Docetaxel—head and neck cancer	0.000217	0.00123	CcSEcCtD
Mesalazine—Loss of consciousness—Docetaxel—head and neck cancer	0.000216	0.00122	CcSEcCtD
Mesalazine—Cough—Docetaxel—head and neck cancer	0.000214	0.00121	CcSEcCtD
Mesalazine—Hypertension—Docetaxel—head and neck cancer	0.000212	0.0012	CcSEcCtD
Mesalazine—Chest pain—Docetaxel—head and neck cancer	0.000209	0.00118	CcSEcCtD
Mesalazine—Myalgia—Docetaxel—head and neck cancer	0.000209	0.00118	CcSEcCtD
Mesalazine—Arthralgia—Docetaxel—head and neck cancer	0.000209	0.00118	CcSEcCtD
Mesalazine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—head and neck cancer	0.000208	0.00118	CcSEcCtD
Mesalazine—Hypersensitivity—Fluorouracil—head and neck cancer	0.000205	0.00116	CcSEcCtD
Mesalazine—Dry mouth—Docetaxel—head and neck cancer	0.000205	0.00116	CcSEcCtD
Mesalazine—Confusional state—Docetaxel—head and neck cancer	0.000202	0.00114	CcSEcCtD
Mesalazine—Anaphylactic shock—Docetaxel—head and neck cancer	0.000201	0.00113	CcSEcCtD
Mesalazine—Oedema—Docetaxel—head and neck cancer	0.000201	0.00113	CcSEcCtD
Mesalazine—Infection—Docetaxel—head and neck cancer	0.000199	0.00113	CcSEcCtD
Mesalazine—Shock—Docetaxel—head and neck cancer	0.000197	0.00112	CcSEcCtD
Mesalazine—Nervous system disorder—Docetaxel—head and neck cancer	0.000197	0.00111	CcSEcCtD
Mesalazine—Pruritus—Fluorouracil—head and neck cancer	0.000197	0.00111	CcSEcCtD
Mesalazine—Thrombocytopenia—Docetaxel—head and neck cancer	0.000196	0.00111	CcSEcCtD
Mesalazine—Tachycardia—Docetaxel—head and neck cancer	0.000196	0.00111	CcSEcCtD
Mesalazine—Skin disorder—Docetaxel—head and neck cancer	0.000195	0.0011	CcSEcCtD
Mesalazine—Anorexia—Docetaxel—head and neck cancer	0.000191	0.00108	CcSEcCtD
Mesalazine—Diarrhoea—Fluorouracil—head and neck cancer	0.00019	0.00108	CcSEcCtD
Mesalazine—Hypotension—Docetaxel—head and neck cancer	0.000187	0.00106	CcSEcCtD
Mesalazine—Dizziness—Fluorouracil—head and neck cancer	0.000184	0.00104	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Docetaxel—head and neck cancer	0.000183	0.00103	CcSEcCtD
Mesalazine—Insomnia—Docetaxel—head and neck cancer	0.000181	0.00103	CcSEcCtD
Mesalazine—Paraesthesia—Docetaxel—head and neck cancer	0.00018	0.00102	CcSEcCtD
Mesalazine—Dyspnoea—Docetaxel—head and neck cancer	0.000179	0.00101	CcSEcCtD
Mesalazine—Somnolence—Docetaxel—head and neck cancer	0.000178	0.00101	CcSEcCtD
Mesalazine—Vomiting—Fluorouracil—head and neck cancer	0.000177	0.000999	CcSEcCtD
Mesalazine—Dyspepsia—Docetaxel—head and neck cancer	0.000177	0.000999	CcSEcCtD
Mesalazine—Rash—Fluorouracil—head and neck cancer	0.000175	0.000991	CcSEcCtD
Mesalazine—Dermatitis—Fluorouracil—head and neck cancer	0.000175	0.00099	CcSEcCtD
Mesalazine—Decreased appetite—Docetaxel—head and neck cancer	0.000174	0.000986	CcSEcCtD
Mesalazine—Headache—Fluorouracil—head and neck cancer	0.000174	0.000985	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Docetaxel—head and neck cancer	0.000173	0.000979	CcSEcCtD
Mesalazine—Fatigue—Docetaxel—head and neck cancer	0.000173	0.000978	CcSEcCtD
Mesalazine—Pain—Docetaxel—head and neck cancer	0.000172	0.00097	CcSEcCtD
Mesalazine—Constipation—Docetaxel—head and neck cancer	0.000172	0.00097	CcSEcCtD
Mesalazine—Feeling abnormal—Docetaxel—head and neck cancer	0.000165	0.000935	CcSEcCtD
Mesalazine—Nausea—Fluorouracil—head and neck cancer	0.000165	0.000934	CcSEcCtD
Mesalazine—Gastrointestinal pain—Docetaxel—head and neck cancer	0.000164	0.000928	CcSEcCtD
Mesalazine—Body temperature increased—Docetaxel—head and neck cancer	0.000159	0.000897	CcSEcCtD
Mesalazine—Abdominal pain—Docetaxel—head and neck cancer	0.000159	0.000897	CcSEcCtD
Mesalazine—Hypersensitivity—Docetaxel—head and neck cancer	0.000148	0.000836	CcSEcCtD
Mesalazine—Asthenia—Docetaxel—head and neck cancer	0.000144	0.000814	CcSEcCtD
Mesalazine—Pruritus—Docetaxel—head and neck cancer	0.000142	0.000803	CcSEcCtD
Mesalazine—Diarrhoea—Docetaxel—head and neck cancer	0.000137	0.000776	CcSEcCtD
Mesalazine—Dizziness—Docetaxel—head and neck cancer	0.000133	0.00075	CcSEcCtD
Mesalazine—Vomiting—Docetaxel—head and neck cancer	0.000128	0.000721	CcSEcCtD
Mesalazine—Rash—Docetaxel—head and neck cancer	0.000126	0.000715	CcSEcCtD
Mesalazine—Dermatitis—Docetaxel—head and neck cancer	0.000126	0.000715	CcSEcCtD
Mesalazine—Headache—Docetaxel—head and neck cancer	0.000126	0.000711	CcSEcCtD
Mesalazine—Nausea—Docetaxel—head and neck cancer	0.000119	0.000674	CcSEcCtD
Mesalazine—PTGS2—Spinal Cord Injury—EGFR—head and neck cancer	7.37e-05	0.000379	CbGpPWpGaD
Mesalazine—CHUK—Integrated Pancreatic Cancer Pathway—PIK3CA—head and neck cancer	7.35e-05	0.000378	CbGpPWpGaD
Mesalazine—CHUK—Downstream signaling of activated FGFR—AKT1—head and neck cancer	7.32e-05	0.000377	CbGpPWpGaD
Mesalazine—PPARG—Circadian rythm related genes—TP53—head and neck cancer	7.27e-05	0.000374	CbGpPWpGaD
Mesalazine—CHUK—Integrated Breast Cancer Pathway—AKT1—head and neck cancer	7.24e-05	0.000373	CbGpPWpGaD
Mesalazine—CHUK—B Cell Activation—PIK3CA—head and neck cancer	7.23e-05	0.000372	CbGpPWpGaD
Mesalazine—CHUK—Signaling by FGFR in disease—HRAS—head and neck cancer	7.22e-05	0.000372	CbGpPWpGaD
Mesalazine—CHUK—Fc epsilon receptor (FCERI) signaling—HRAS—head and neck cancer	7.22e-05	0.000372	CbGpPWpGaD
Mesalazine—CHUK—DAP12 interactions—HRAS—head and neck cancer	7.22e-05	0.000372	CbGpPWpGaD
Mesalazine—CHUK—Signaling by ERBB4—AKT1—head and neck cancer	7.21e-05	0.000371	CbGpPWpGaD
Mesalazine—CHUK—Signaling by EGFR—HRAS—head and neck cancer	7.16e-05	0.000369	CbGpPWpGaD
Mesalazine—IKBKB—MAPK Signaling Pathway—TP53—head and neck cancer	7.14e-05	0.000368	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—KISS1—head and neck cancer	7.11e-05	0.000366	CbGpPWpGaD
Mesalazine—CHUK—Integrated Pancreatic Cancer Pathway—TP53—head and neck cancer	7.11e-05	0.000366	CbGpPWpGaD
Mesalazine—IKBKB—Insulin Signaling—HRAS—head and neck cancer	7.1e-05	0.000366	CbGpPWpGaD
Mesalazine—CHUK—Signaling by EGFR in Cancer—HRAS—head and neck cancer	7.1e-05	0.000365	CbGpPWpGaD
Mesalazine—IKBKB—Fc epsilon receptor (FCERI) signaling—PIK3CA—head and neck cancer	7.08e-05	0.000364	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—YAP1—head and neck cancer	7.07e-05	0.000364	CbGpPWpGaD
Mesalazine—CHUK—Signaling by PDGF—HRAS—head and neck cancer	7.07e-05	0.000364	CbGpPWpGaD
Mesalazine—IKBKB—Regulation of toll-like receptor signaling pathway—AKT1—head and neck cancer	7.02e-05	0.000361	CbGpPWpGaD
Mesalazine—CHUK—NGF signalling via TRKA from the plasma membrane—PIK3CA—head and neck cancer	6.92e-05	0.000356	CbGpPWpGaD
Mesalazine—CHUK—Downstream signal transduction—AKT1—head and neck cancer	6.88e-05	0.000354	CbGpPWpGaD
Mesalazine—IKBKB—Downstream signaling events of B Cell Receptor (BCR)—HRAS—head and neck cancer	6.86e-05	0.000353	CbGpPWpGaD
Mesalazine—CHUK—Cytokine Signaling in Immune system—STAT3—head and neck cancer	6.86e-05	0.000353	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—TYMS—head and neck cancer	6.86e-05	0.000353	CbGpPWpGaD
Mesalazine—CHUK—Signaling by FGFR—AKT1—head and neck cancer	6.85e-05	0.000352	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by NGF—PTEN—head and neck cancer	6.84e-05	0.000352	CbGpPWpGaD
Mesalazine—IKBKB—BDNF signaling pathway—AKT1—head and neck cancer	6.82e-05	0.000351	CbGpPWpGaD
Mesalazine—CHUK—Signaling by ERBB2—AKT1—head and neck cancer	6.81e-05	0.000351	CbGpPWpGaD
Mesalazine—CHUK—DAP12 signaling—AKT1—head and neck cancer	6.78e-05	0.000349	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—GSTM1—head and neck cancer	6.78e-05	0.000349	CbGpPWpGaD
Mesalazine—CHUK—Signaling by NGF—STAT3—head and neck cancer	6.74e-05	0.000347	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—BCL2L1—head and neck cancer	6.71e-05	0.000345	CbGpPWpGaD
Mesalazine—CHUK—B Cell Activation—HRAS—head and neck cancer	6.69e-05	0.000344	CbGpPWpGaD
Mesalazine—CHUK—Downstream signaling events of B Cell Receptor (BCR)—AKT1—head and neck cancer	6.68e-05	0.000344	CbGpPWpGaD
Mesalazine—CHUK—Cytokine Signaling in Immune system—MAPK3—head and neck cancer	6.55e-05	0.000337	CbGpPWpGaD
Mesalazine—IKBKB—B Cell Activation—PIK3CA—head and neck cancer	6.55e-05	0.000337	CbGpPWpGaD
Mesalazine—IKBKB—Fc epsilon receptor (FCERI) signaling—HRAS—head and neck cancer	6.55e-05	0.000337	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—GPX1—head and neck cancer	6.49e-05	0.000334	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—GRP—head and neck cancer	6.46e-05	0.000333	CbGpPWpGaD
Mesalazine—CHUK—Signaling by NGF—MAPK3—head and neck cancer	6.44e-05	0.000332	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—CYP1A1—head and neck cancer	6.43e-05	0.000331	CbGpPWpGaD
Mesalazine—CHUK—NGF signalling via TRKA from the plasma membrane—HRAS—head and neck cancer	6.4e-05	0.000329	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—head and neck cancer	6.39e-05	0.000329	CbGpPWpGaD
Mesalazine—CHUK—Signaling by FGFR in disease—AKT1—head and neck cancer	6.38e-05	0.000328	CbGpPWpGaD
Mesalazine—CHUK—DAP12 interactions—AKT1—head and neck cancer	6.38e-05	0.000328	CbGpPWpGaD
Mesalazine—CHUK—Fc epsilon receptor (FCERI) signaling—AKT1—head and neck cancer	6.38e-05	0.000328	CbGpPWpGaD
Mesalazine—CHUK—Signaling by EGFR—AKT1—head and neck cancer	6.32e-05	0.000325	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	6.32e-05	0.000325	CbGpPWpGaD
Mesalazine—IKBKB—Insulin Signaling—AKT1—head and neck cancer	6.27e-05	0.000323	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—STAT6—head and neck cancer	6.27e-05	0.000323	CbGpPWpGaD
Mesalazine—CHUK—Signaling by EGFR in Cancer—AKT1—head and neck cancer	6.27e-05	0.000323	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	6.26e-05	0.000322	CbGpPWpGaD
Mesalazine—CHUK—Signaling by PDGF—AKT1—head and neck cancer	6.24e-05	0.000321	CbGpPWpGaD
Mesalazine—CHUK—Cytokine Signaling in Immune system—MAPK1—head and neck cancer	6.23e-05	0.000321	CbGpPWpGaD
Mesalazine—IKBKB—Cytokine Signaling in Immune system—STAT3—head and neck cancer	6.22e-05	0.00032	CbGpPWpGaD
Mesalazine—PTGS2—Spinal Cord Injury—TP53—head and neck cancer	6.19e-05	0.000319	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—head and neck cancer	6.17e-05	0.000318	CbGpPWpGaD
Mesalazine—CHUK—Signaling by NGF—MAPK1—head and neck cancer	6.13e-05	0.000316	CbGpPWpGaD
Mesalazine—CHUK—Signaling by NGF—EGFR—head and neck cancer	6.13e-05	0.000316	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by NGF—STAT3—head and neck cancer	6.11e-05	0.000315	CbGpPWpGaD
Mesalazine—IKBKB—B Cell Activation—HRAS—head and neck cancer	6.06e-05	0.000312	CbGpPWpGaD
Mesalazine—IKBKB—Downstream signaling events of B Cell Receptor (BCR)—AKT1—head and neck cancer	6.06e-05	0.000312	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—CASP8—head and neck cancer	6.05e-05	0.000311	CbGpPWpGaD
Mesalazine—IKBKB—MAPK Signaling Pathway—AKT1—head and neck cancer	6.03e-05	0.00031	CbGpPWpGaD
Mesalazine—CHUK—Integrated Pancreatic Cancer Pathway—AKT1—head and neck cancer	6e-05	0.000309	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—NAT2—head and neck cancer	5.95e-05	0.000306	CbGpPWpGaD
Mesalazine—IKBKB—Cytokine Signaling in Immune system—MAPK3—head and neck cancer	5.94e-05	0.000306	CbGpPWpGaD
Mesalazine—CHUK—B Cell Activation—AKT1—head and neck cancer	5.9e-05	0.000304	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—GRP—head and neck cancer	5.86e-05	0.000302	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by NGF—MAPK3—head and neck cancer	5.84e-05	0.000301	CbGpPWpGaD
Mesalazine—IKBKB—Fc epsilon receptor (FCERI) signaling—AKT1—head and neck cancer	5.78e-05	0.000298	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—CDH1—head and neck cancer	5.74e-05	0.000295	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—STAT6—head and neck cancer	5.69e-05	0.000293	CbGpPWpGaD
Mesalazine—IKBKB—Cytokine Signaling in Immune system—MAPK1—head and neck cancer	5.65e-05	0.000291	CbGpPWpGaD
Mesalazine—CHUK—NGF signalling via TRKA from the plasma membrane—AKT1—head and neck cancer	5.65e-05	0.000291	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—head and neck cancer	5.57e-05	0.000287	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by NGF—MAPK1—head and neck cancer	5.56e-05	0.000286	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by NGF—EGFR—head and neck cancer	5.56e-05	0.000286	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—YAP1—head and neck cancer	5.55e-05	0.000286	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—CASP8—head and neck cancer	5.49e-05	0.000282	CbGpPWpGaD
Mesalazine—CHUK—Cytokine Signaling in Immune system—PIK3CA—head and neck cancer	5.41e-05	0.000279	CbGpPWpGaD
Mesalazine—IKBKB—B Cell Activation—AKT1—head and neck cancer	5.35e-05	0.000276	CbGpPWpGaD
Mesalazine—CHUK—Signaling by NGF—PIK3CA—head and neck cancer	5.32e-05	0.000274	CbGpPWpGaD
Mesalazine—PPARG—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	5.31e-05	0.000273	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	5.28e-05	0.000272	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK3—head and neck cancer	5.27e-05	0.000271	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—DPYD—head and neck cancer	5.22e-05	0.000269	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—CDH1—head and neck cancer	5.2e-05	0.000268	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—BCL2—head and neck cancer	5.19e-05	0.000267	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—YAP1—head and neck cancer	5.03e-05	0.000259	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	5.02e-05	0.000258	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK1—head and neck cancer	5.02e-05	0.000258	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—head and neck cancer	5.01e-05	0.000258	CbGpPWpGaD
Mesalazine—CHUK—Cytokine Signaling in Immune system—HRAS—head and neck cancer	5.01e-05	0.000258	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	4.97e-05	0.000256	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—YAP1—head and neck cancer	4.95e-05	0.000255	CbGpPWpGaD
Mesalazine—CHUK—Signaling by NGF—HRAS—head and neck cancer	4.92e-05	0.000253	CbGpPWpGaD
Mesalazine—IKBKB—Cytokine Signaling in Immune system—PIK3CA—head and neck cancer	4.91e-05	0.000253	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by NGF—PIK3CA—head and neck cancer	4.82e-05	0.000248	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—NAT2—head and neck cancer	4.72e-05	0.000243	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—BCL2—head and neck cancer	4.71e-05	0.000242	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—VEGFA—head and neck cancer	4.69e-05	0.000241	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—STAT3—head and neck cancer	4.64e-05	0.000239	CbGpPWpGaD
Mesalazine—PPARG—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	4.63e-05	0.000238	CbGpPWpGaD
Mesalazine—IKBKB—Cytokine Signaling in Immune system—HRAS—head and neck cancer	4.54e-05	0.000234	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by NGF—HRAS—head and neck cancer	4.46e-05	0.00023	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—MAPK3—head and neck cancer	4.43e-05	0.000228	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—head and neck cancer	4.35e-05	0.000224	CbGpPWpGaD
Mesalazine—CHUK—Signaling by NGF—AKT1—head and neck cancer	4.35e-05	0.000224	CbGpPWpGaD
Mesalazine—CHUK—Immune System—BCL2L1—head and neck cancer	4.31e-05	0.000222	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—PTEN—head and neck cancer	4.3e-05	0.000221	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—TYMS—head and neck cancer	4.25e-05	0.000219	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—MAPK1—head and neck cancer	4.22e-05	0.000217	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—EGFR—head and neck cancer	4.22e-05	0.000217	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—head and neck cancer	4.21e-05	0.000217	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—GSTM1—head and neck cancer	4.2e-05	0.000216	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—DPYD—head and neck cancer	4.14e-05	0.000213	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—PTEN—head and neck cancer	4.13e-05	0.000213	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—NOTCH1—head and neck cancer	4.1e-05	0.000211	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—GPX1—head and neck cancer	4.02e-05	0.000207	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—CYP1A1—head and neck cancer	3.98e-05	0.000205	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by NGF—AKT1—head and neck cancer	3.94e-05	0.000203	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—YAP1—head and neck cancer	3.93e-05	0.000202	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—BCL2L1—head and neck cancer	3.91e-05	0.000201	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—PTEN—head and neck cancer	3.9e-05	0.000201	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—PTGS2—head and neck cancer	3.82e-05	0.000197	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—PTEN—head and neck cancer	3.74e-05	0.000193	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	3.72e-05	0.000192	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—MAPK3—head and neck cancer	3.67e-05	0.000189	CbGpPWpGaD
Mesalazine—CHUK—Disease—NOTCH1—head and neck cancer	3.57e-05	0.000184	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—head and neck cancer	3.56e-05	0.000183	CbGpPWpGaD
Mesalazine—CHUK—Immune System—CASP8—head and neck cancer	3.52e-05	0.000181	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—MAPK1—head and neck cancer	3.5e-05	0.00018	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—EGFR—head and neck cancer	3.5e-05	0.00018	CbGpPWpGaD
Mesalazine—CHUK—Immune System—CDH1—head and neck cancer	3.48e-05	0.000179	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—HRAS—head and neck cancer	3.39e-05	0.000174	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—EGFR—head and neck cancer	3.36e-05	0.000173	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—PTEN—head and neck cancer	3.33e-05	0.000172	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—MAPK3—head and neck cancer	3.33e-05	0.000172	CbGpPWpGaD
Mesalazine—PPARG—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	3.27e-05	0.000168	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	3.25e-05	0.000167	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CASP8—head and neck cancer	3.19e-05	0.000164	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—MAPK1—head and neck cancer	3.17e-05	0.000163	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—EGFR—head and neck cancer	3.17e-05	0.000163	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CDH1—head and neck cancer	3.16e-05	0.000163	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—EGFR—head and neck cancer	3.04e-05	0.000157	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—PIK3CA—head and neck cancer	3.03e-05	0.000156	CbGpPWpGaD
Mesalazine—CHUK—Immune System—BCL2—head and neck cancer	3.02e-05	0.000156	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—AKT1—head and neck cancer	2.99e-05	0.000154	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—TYMS—head and neck cancer	2.97e-05	0.000153	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—GSTM1—head and neck cancer	2.94e-05	0.000151	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—PIK3CA—head and neck cancer	2.91e-05	0.00015	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—GPX1—head and neck cancer	2.81e-05	0.000145	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—HRAS—head and neck cancer	2.81e-05	0.000144	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—CYP1A1—head and neck cancer	2.79e-05	0.000143	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—PIK3CA—head and neck cancer	2.75e-05	0.000142	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—BCL2—head and neck cancer	2.74e-05	0.000141	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—HRAS—head and neck cancer	2.7e-05	0.000139	CbGpPWpGaD
Mesalazine—CHUK—Immune System—IL2—head and neck cancer	2.66e-05	0.000137	CbGpPWpGaD
Mesalazine—CHUK—Disease—PTGS2—head and neck cancer	2.65e-05	0.000137	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—PIK3CA—head and neck cancer	2.64e-05	0.000136	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	2.58e-05	0.000133	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—HRAS—head and neck cancer	2.55e-05	0.000131	CbGpPWpGaD
Mesalazine—CHUK—Immune System—PTEN—head and neck cancer	2.5e-05	0.000129	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—NOTCH1—head and neck cancer	2.5e-05	0.000129	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—AKT1—head and neck cancer	2.48e-05	0.000128	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—HRAS—head and neck cancer	2.44e-05	0.000126	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—IL2—head and neck cancer	2.41e-05	0.000124	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—AKT1—head and neck cancer	2.38e-05	0.000123	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PTGS2—head and neck cancer	2.37e-05	0.000122	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—TYMS—head and neck cancer	2.36e-05	0.000122	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—PIK3CA—head and neck cancer	2.35e-05	0.000121	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—GSTM1—head and neck cancer	2.33e-05	0.00012	CbGpPWpGaD
Mesalazine—CHUK—Disease—PTEN—head and neck cancer	2.31e-05	0.000119	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	2.29e-05	0.000118	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—PTEN—head and neck cancer	2.27e-05	0.000117	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—NOTCH1—head and neck cancer	2.27e-05	0.000117	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—MAPK3—head and neck cancer	2.27e-05	0.000117	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—AKT1—head and neck cancer	2.25e-05	0.000116	CbGpPWpGaD
Mesalazine—CHUK—Immune System—STAT3—head and neck cancer	2.24e-05	0.000115	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—GPX1—head and neck cancer	2.23e-05	0.000115	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—CYP1A1—head and neck cancer	2.21e-05	0.000114	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—AKT1—head and neck cancer	2.16e-05	0.000111	CbGpPWpGaD
Mesalazine—CHUK—Immune System—MAPK3—head and neck cancer	2.14e-05	0.00011	CbGpPWpGaD
Mesalazine—PTGS2—Disease—NOTCH1—head and neck cancer	2.12e-05	0.000109	CbGpPWpGaD
Mesalazine—CHUK—Disease—STAT3—head and neck cancer	2.07e-05	0.000106	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PTEN—head and neck cancer	2.06e-05	0.000106	CbGpPWpGaD
Mesalazine—CHUK—Immune System—MAPK1—head and neck cancer	2.04e-05	0.000105	CbGpPWpGaD
Mesalazine—CHUK—Immune System—EGFR—head and neck cancer	2.04e-05	0.000105	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—STAT3—head and neck cancer	2.03e-05	0.000105	CbGpPWpGaD
Mesalazine—CHUK—Disease—MAPK3—head and neck cancer	1.98e-05	0.000102	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—MAPK3—head and neck cancer	1.94e-05	9.99e-05	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—AKT1—head and neck cancer	1.92e-05	9.89e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—MAPK1—head and neck cancer	1.88e-05	9.68e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—EGFR—head and neck cancer	1.88e-05	9.68e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—MAPK1—head and neck cancer	1.85e-05	9.51e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—EGFR—head and neck cancer	1.85e-05	9.5e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	1.82e-05	9.36e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—PIK3CA—head and neck cancer	1.77e-05	9.1e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—IL2—head and neck cancer	1.72e-05	8.86e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CCND1—head and neck cancer	1.68e-05	8.64e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PTGS2—head and neck cancer	1.66e-05	8.53e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—HRAS—head and neck cancer	1.63e-05	8.42e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—PIK3CA—head and neck cancer	1.63e-05	8.4e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PTEN—head and neck cancer	1.62e-05	8.34e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—PIK3CA—head and neck cancer	1.6e-05	8.25e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—IL2—head and neck cancer	1.56e-05	8.03e-05	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—AKT1—head and neck cancer	1.53e-05	7.87e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CCND1—head and neck cancer	1.52e-05	7.83e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—HRAS—head and neck cancer	1.51e-05	7.77e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—HRAS—head and neck cancer	1.48e-05	7.63e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PTEN—head and neck cancer	1.47e-05	7.56e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—VEGFA—head and neck cancer	1.46e-05	7.53e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PIK3CA—head and neck cancer	1.46e-05	7.49e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—STAT3—head and neck cancer	1.45e-05	7.46e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PTEN—head and neck cancer	1.45e-05	7.44e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—AKT1—head and neck cancer	1.44e-05	7.43e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—MAPK3—head and neck cancer	1.38e-05	7.12e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—PTEN—head and neck cancer	1.37e-05	7.05e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—AKT1—head and neck cancer	1.33e-05	6.86e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—VEGFA—head and neck cancer	1.33e-05	6.83e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—MAPK1—head and neck cancer	1.32e-05	6.78e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—EGFR—head and neck cancer	1.32e-05	6.78e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—STAT3—head and neck cancer	1.31e-05	6.76e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—AKT1—head and neck cancer	1.31e-05	6.74e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MAPK3—head and neck cancer	1.25e-05	6.46e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—STAT3—head and neck cancer	1.23e-05	6.31e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MAPK1—head and neck cancer	1.19e-05	6.15e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—EGFR—head and neck cancer	1.19e-05	6.14e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—AKT1—head and neck cancer	1.19e-05	6.12e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—MAPK3—head and neck cancer	1.17e-05	6.03e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PTEN—head and neck cancer	1.15e-05	5.91e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PIK3CA—head and neck cancer	1.14e-05	5.88e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—MAPK1—head and neck cancer	1.11e-05	5.73e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—EGFR—head and neck cancer	1.11e-05	5.73e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—TP53—head and neck cancer	1.11e-05	5.69e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—HRAS—head and neck cancer	1.06e-05	5.44e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PIK3CA—head and neck cancer	1.04e-05	5.33e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PIK3CA—head and neck cancer	1.02e-05	5.25e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—TP53—head and neck cancer	1e-05	5.16e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—PIK3CA—head and neck cancer	9.66e-06	4.97e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—HRAS—head and neck cancer	9.58e-06	4.93e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—AKT1—head and neck cancer	9.33e-06	4.8e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—HRAS—head and neck cancer	8.94e-06	4.6e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—AKT1—head and neck cancer	8.46e-06	4.36e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—AKT1—head and neck cancer	8.33e-06	4.29e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PIK3CA—head and neck cancer	8.09e-06	4.17e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—AKT1—head and neck cancer	7.89e-06	4.06e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—AKT1—head and neck cancer	6.61e-06	3.4e-05	CbGpPWpGaD
